Zhang Xiaoming, Guo Yibing, Fang Kun, Huang Xiangqian, Lan Duo, Wang Mengqi, Jia Lina, Ji Xunming, Meng Ran, Zhou Da
Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China; Advanced Center of Stroke, Beijing Institute for Brain Disorders, Beijing 100053, China; National Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Capital Medical University, Beijing 100069, China.
Brain Res Bull. 2025 Feb;221:111219. doi: 10.1016/j.brainresbull.2025.111219. Epub 2025 Jan 19.
Ischemic stroke (IS) remains a significant global health burden, necessitating the development of novel therapeutic strategies. This study aims to systematically evaluate the therapeutic effects of mesenchymal stem cell-derived exosomes (MSC-Exos) on IS outcomes in rodent models.
A comprehensive literature search was conducted across multiple databases to identify studies investigating the effects of MSC-Exos on rodent models of IS. Following rigorous inclusion and exclusion criteria, 73 high-quality studies were selected for meta-analysis. Primary outcomes included reductions in infarct volume/ratio and improvements in functional recovery scores. Data extraction and analysis were performed using RevMan 5.3 software.
Pooled data indicated that MSC-Exos administration significantly reduced infarct size and improved functional recovery scores in rodent models of IS. Treatment within 24 hours and beyond 24 hours of stroke induction both demonstrated substantial reductions in infarct volume/ratio compared to controls. Furthermore, MSC-Exos-treated groups exhibited marked improvements in functional recovery, as assessed by various neurobehavioral tests. The meta-analysis showed no significant publication bias, and heterogeneity levels were acceptable.
MSC-Exos reveal significant therapeutic potential for IS, with evidence supporting their efficacy in reducing infarct size and enhancing functional recovery in preclinical rodent models. These findings pave the way for further research and potential clinical translation.
缺血性卒中（IS）仍然是一项重大的全球健康负担，因此需要开发新的治疗策略。本研究旨在系统评价间充质干细胞来源的外泌体（MSC-Exos）对啮齿动物模型缺血性卒中结局的治疗效果。
在多个数据库中进行全面的文献检索，以识别研究MSC-Exos对缺血性卒中啮齿动物模型影响的研究。遵循严格的纳入和排除标准，选择73项高质量研究进行荟萃分析。主要结局包括梗死体积/比例的降低和功能恢复评分的改善。使用RevMan 5.3软件进行数据提取和分析。
汇总数据表明，在缺血性卒中啮齿动物模型中，给予MSC-Exos可显著减小梗死面积并改善功能恢复评分。与对照组相比，在卒中诱导后24小时内及24小时后进行治疗均显示梗死体积/比例大幅降低。此外，通过各种神经行为测试评估，接受MSC-Exos治疗的组在功能恢复方面表现出显著改善。荟萃分析显示无显著的发表偏倚，异质性水平可接受。
MSC-Exos对缺血性卒中有显著的治疗潜力，有证据支持其在临床前啮齿动物模型中减小梗死面积和促进功能恢复的疗效。这些发现为进一步研究和潜在的临床转化铺平了道路。
